ArticleNature communications2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models.
Connor A Ott et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it